These outcomes suggest that FXR might reduce cholesterol biosynthesis by inhibiting the PI3K/AKT/mTOR signaling pathway and subsequently decreasing the expression of SREBP2 and HMGCR in human TSGH8301 and T24 bladder cancer cells. The gene discussed is SREBF2; the disease is urinary bladder cancer.